Full Press Release Details
SOUTH SAN FRANCISCO, Calif., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer, and members of Pliant’s senior management will participate in the following September investor conferences:
Citi's 17th Annual BioPharma Conference on September 6 – 7, 2022 at the Four Seasons Hotel, Boston, Massachusetts
H.C. Wainwright 24th Annual Global Investment Conference virtually on September 12 – 14, 2022. Dr Coulie’s pre-recorded fireside chat will be available on Monday, September 12, 2022, at 7:00 a.m. ET
Interested parties can access the H.C. Wainwright fireside chat from the Investor Relations’ Events & Presentation page of Pliant’s website at https://ir.pliantrx.com/news-and-events/events-and-presentations with an audio archive available for 30 days from the time it is made available.
About Pliant Therapeutics, Inc.
Investor and Media Contact:
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.